|
The Madrina Network Web Portal
|
5R44CA177037-03
|
$688,585
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
Minimally invasive image-guided tumor ablation in an oncogenic pig model
|
5R21CA195433-02
|
$266,380
|
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-05
|
$660,173
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-02
|
$409,153
|
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Establishment of a patient-like mouse models of soft-tissue sarcoma sub-types
|
1R43CA213649-01
|
$224,700
|
|
HOFFMAN, ROBERT
|
ANTICANCER, INC.
|
|
Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer
|
5R44CA203199-02
|
$402,226
|
|
TAYLOR, IAN
|
ARVINAS, INC.
|
|
P53 inactivation on MDSC development and tumor progression
|
5R01CA169133-05
|
$315,400
|
|
CUI, YAN
|
AUGUSTA UNIVERSITY
|
|
Allogeneic antibody therapy for malignant mesothelioma
|
5R03CA205713-02
|
$79,250
|
|
BURT, BRYAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis
|
1R01CA204926-01A1
|
$362,569
|
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics
|
1R01CA205594-01A1
|
$362,569
|
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-12
|
$249,637
|
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Managing chemotherapy induced neuropathy in Cancer patients using ExerGaming
|
5R21CA190933-02
|
$199,119
|
|
NAJAFI, BIJAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
5R01CA193235-03
|
$462,191
|
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
High-Throughput Functional Annotation of Fusion Gene Cancer Drivers
|
5R21CA198320-02
|
$207,235
|
|
SCOTT, KENNETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Reprogramming of Prostate Stromal Cells by Prostate Inflammation
|
5R21CA196570-02
|
$185,247
|
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integrating Palliative Oncology Care into Doctor of Nursing Practice Programs
|
5R25CA171960-05
|
$260,812
|
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Training Healthcare Professionals to Implement Biopsychosocial Screening
|
5R25CA174444-05
|
$277,797
|
|
LOSCALZO, MATTHEW
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
|
5R01CA201496-02
|
$463,530
|
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Hyperpolarized NMR for Studies of Cancer Therapies Targeting the Warburg Effect
|
5R01CA169470-05
|
$361,050
|
|
GRANT, AARON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Cbx-3/HP-1gamma deficiency confers anti-tumor immunity
|
5R21CA198263-02
|
$225,765
|
|
THAI, TO-HA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Defining driver tumor-suppressors for melanoma using the zebrafish
|
5K99CA201465-02
|
$171,990
|
|
ABLAIN, JULIEN
|
BOSTON CHILDREN'S HOSPITAL
|
|
Structure and Assembly of Viruses
|
5R01CA013202-46
|
$384,600
|
|
HARRISON, STEPHEN
|
BOSTON CHILDREN'S HOSPITAL
|
|
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause
|
5R01CA185530-04
|
$367,275
|
|
MOSES, MARSHA
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of diagnostic and prognostic tests for esophageal adenocarcinoma
|
1R01CA208599-01A1
|
$646,502
|
|
GODFREY, TONY
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Planning for NCDs Research Center of Excellence in Southern Africa
|
5P20CA210283-02
|
$236,966
|
$118,483
|
TAPELA, NEO
|
BOTSWANA-HARVARD AIDS INSTITUTE
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-04
|
$11,145,123
|
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Co-targeting oncogenic pathways in advanced prostate cancer
|
5R01CA198097-02
|
$381,212
|
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Selenoproteins as targets for cancer prevention
|
5R01CA080946-17
|
$316,004
|
|
GLADYSHEV, VADIM
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
De-Regulation of 5hmC/TET2 Tumor Suppressor under Anti-Estrogen Therapy
|
5R01CA194302-02
|
$405,036
|
|
SHI, YUJIANG
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Examining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancer
|
5R01CA197780-02
|
$363,581
|
|
DIFEO, ANALISA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention
|
5R01CA168586-05
|
$328,888
|
|
LETTERIO, JOHN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Defining the role of the PR72 regulatory subunit in small molecule mediated activation of PP2A's tumor suppressive activity
|
1F31CA213554-01
|
$37,644
|
|
PERL, ABBEY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis
|
5R01CA177069-05
|
$328,265
|
|
SCHIEMANN, WILLIAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
|
1R41CA213463-01
|
$300,000
|
|
SZABO, CSABA
|
CBS THERAPEUTICS, INC.
|
|
Differential MRI imaging for brain tumor metastases diagnosis and treatment monitoring
|
5R01CA188743-03
|
$511,546
|
|
LJUBIMOVA, JULIA
|
CEDARS-SINAI MEDICAL CENTER
|
|
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY
|
5R01CA177852-03
|
$380,640
|
|
HANCOCK, WAYNE
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Myc - miR-17-92 axis in colorectal cancers
|
5R01CA196299-03
|
$384,300
|
|
THOMAS-TIKHONENKO, ANDREI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Viral Modulation of Genetic Stability
|
5R01CA097093-14
|
$399,000
|
|
WEITZMAN, MATTHEW
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Functional Inhibition of Deubiquitylase HAUSP to Disrupt Glioblastoma Stem Cells
|
5R01CA184090-03
|
$362,569
|
|
BAO, SHIDENG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Modulation of MicroRNAs with Xenobiotics to Target c-Myc
|
5R01CA177810-03
|
$368,974
|
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
MYC as a Biomarker in Aggressive Non-Hodgkin Lymphoma
|
5R01CA187415-03
|
$448,485
|
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Cooperative steroidogenic inhibition for treatment of advanced prostate cancer
|
5R01CA168899-05
|
$326,897
|
|
SHARIFI, NIMA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
CSHL Quantitative Imaging: From Cells to Molecules Course
|
4R25CA078139-19
|
$102,233
|
|
GRODZICKER, TERRI
|
COLD SPRING HARBOR LABORATORY
|
|
Programmable Probiotics for Cancer
|
5R00CA197649-03
|
$220,680
|
|
DANINO, TAL
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Cook For Your Life: Maintaining diet and physical activity changes in Latina breast cancer survivors
|
5R01CA186080-03
|
$597,551
|
|
GREENLEE, HEATHER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Large-Scale Integration of Single Cell RNA-Seq and High-Content Imaging for Analyzing Drug Response in Cancer
|
5R33CA202827-02
|
$316,149
|
|
SIMS, PETER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of wild-type KRAS in the context of tumor profession and metastasis
|
5R01CA178445-03
|
$462,118
|
|
SU, GLORIA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Efficacy of bariatric surgery to decrease the risk of colorectal cancer in mice
|
5R21CA195002-02
|
$168,563
|
|
CUMMINGS, BETHANY
|
CORNELL UNIVERSITY
|
|
Androgen Receptor: A Key Regulator of TRAIL Resistance in Breast Cancer?
|
5R21CA193271-02
|
$160,950
|
|
TU, YAPING
|
CREIGHTON UNIVERSITY
|
|
Quantitative Radiomics System Decoding the Tumor Phenotype
|
5U24CA194354-03
|
$778,713
|
|
AERTS, HUGO
|
DANA-FARBER CANCER INST
|
Total relevant funding to Vascular Disease for this search: $1,987,916
|